Henri Bounameaux

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3034241/publications.pdf

Version: 2024-02-01

7348 34100 23,795 160 52 152 citations h-index g-index papers 163 163 163 15238 citing authors docs citations times ranked all docs

#	Article	IF	Citations
1	Antithrombotic Therapy for VTE Disease. Chest, 2016, 149, 315-352.	0.8	4,060
2	Antithrombotic Therapy for VTE Disease. Chest, 2012, 141, e419S-e496S.	0.8	3,745
3	2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. European Heart Journal, 2014, 35, 3033-3080.	2.2	2,591
4	Prediction of Pulmonary Embolism in the Emergency Department: The Revised Geneva Score. Annals of Internal Medicine, 2006, 144, 165.	3.9	851
5	Pulmonary embolism and deep vein thrombosis. Lancet, The, 2012, 379, 1835-1846.	13.7	809
6	Non-invasive diagnosis of venous thromboembolism in outpatients. Lancet, The, 1999, 353, 190-195.	13.7	800
7	Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism. New England Journal of Medicine, 2003, 348, 1425-1434.	27.0	771
8	Age-Adjusted D-Dimer Cutoff Levels to Rule Out Pulmonary Embolism. JAMA - Journal of the American Medical Association, 2014, 311, 1117.	7.4	680
9	Multidetector-Row Computed Tomography in Suspected Pulmonary Embolism. New England Journal of Medicine, 2005, 352, 1760-1768.	27.0	593
10	Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. New England Journal of Medicine, 2017, 376, 1211-1222.	27.0	577
11	2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncology, The, 2019, 20, e566-e581.	10.7	458
12	Diagnosis of pulmonary embolism by multidetector CT alone or combined with venous ultrasonography of the leg: a randomised non-inferiority trial. Lancet, The, 2008, 371, 1343-1352.	13.7	375
13	Antithrombotic Therapy for VTE Disease. Chest, 2021, 160, e545-e608.	0.8	357
14	Diagnosing pulmonary embolism in outpatients with clinical assessment, D-Dimer measurement, venous ultrasound, and helical computed tomography: a multicenter management study. American Journal of Medicine, 2004, 116, 291-299.	1.5	355
15	International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncology, The, 2016, 17, e452-e466.	10.7	315
16	Effects of age on the performance of common diagnostic tests for pulmonary embolism. American Journal of Medicine, 2000, 109, 357-361.	1.5	276
17	Performance of Helical Computed Tomography in Unselected Outpatients with Suspected Pulmonary Embolism. Annals of Internal Medicine, 2001, 135, 88.	3.9	276
18	Ximelagatran vs Low-Molecular-Weight Heparin and Warfarin for the Treatment of Deep Vein Thrombosis. JAMA - Journal of the American Medical Association, 2005, 293, 681.	7.4	274

#	Article	IF	Citations
19	Vorapaxar in Patients With Peripheral Artery Disease. Circulation, 2013, 127, 1522-1529.	1.6	261
20	D-dimer Testing for Suspected Pulmonary Embolism in Outpatients. American Journal of Respiratory and Critical Care Medicine, 1997, 156, 492-496.	5.6	260
21	Comparison of two clinical prediction rules and implicit assessment among patients with suspected pulmonary embolism. American Journal of Medicine, 2002, 113, 269-275.	1.5	214
22	A positive compression ultrasonography of the lower limb veins is highly predictive of pulmonary embolism on computed tomography in suspected patients. Thrombosis and Haemostasis, 2006, 95, 963-966.	3.4	203
23	Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. Blood, 2016, 127, 1417-1425.	1.4	156
24	Impending Paradoxical Embolism. Chest, 2010, 137, 164-170.	0.8	144
25	Prospective randomized trial comparing endovenous laser ablation and surgery for treatment of primary great saphenous varicose veins with a 2-year follow-up. Journal of Vascular Surgery, 2010, 52, 1234-1241.	1.1	143
26	Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial. Lancet Haematology, the, 2016, 3, e556-e562.	4.6	135
27	Contribution of a New, Rapid, Individual and Quantitative Automated D-Dimer ELISA to Exclude Pulmonary Embolism. Thrombosis and Haemostasis, 1996, 75, 011-013.	3.4	130
28	D-Dimer plasma concentration in various clinical conditions: Implication for the use of this test in the diagnostic approach of venous thromboembolism. Thrombosis Research, 1993, 69, 125-130.	1.7	128
29	Measurement of Plasma D-Dimer for Diagnosis of Deep Venous Thrombosis. American Journal of Clinical Pathology, 1989, 91, 82-85.	0.7	126
30	Factor V Leiden paradox: risk of deepvein thrombosis but not of pulmonary embolism. Lancet, The, 2000, 356, 182-183.	13.7	112
31	Adverse Skin Reactions to Low Molecular Weight Heparins. Drug Safety, 1999, 20, 515-525.	3.2	110
32	Edoxaban. Drugs, 2011, 71, 1503-1526.	10.9	98
33	Cost-Effectiveness Analysis of Diagnostic Strategies for Suspected Pulmonary Embolism Including Helical Computed Tomography. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 39-44.	5.6	94
34	Using an age-dependent D-dimer cut-off value increases the number of older patients in whom deep vein thrombosis can be safely excluded. Haematologica, 2012, 97, 1507-1513.	3.5	93
35	The Challenge of Diagnosing Pulmonary Embolism in Elderly Patients: Influence of Age on Commonly Used Diagnostic Tests and Strategies. Journal of the American Geriatrics Society, 2005, 53, 1039-1045.	2.6	88
36	Red blood cell methylfolate and plasma homocysteine as risk factors for venous thromboembolism: a matched case-control study. Lancet, The, 2002, 359, 747-752.	13.7	87

#	Article	lF	Citations
37	Edoxaban: An Update on the New Oral Direct Factor Xa Inhibitor. Drugs, 2014, 74, 1209-1231.	10.9	84
38	Antiplatelet Drug Response Status Does Not Predict Recurrent Ischemic Events in Stable Cardiovascular Patients. Circulation, 2012, 125, 3201-3210.	1.6	82
39	Characteristics and Management of Patients with Venous Thromboembolism: The GARFIELD-VTE Registry. Thrombosis and Haemostasis, 2019, 119, 319-327.	3.4	76
40	Comparison of four strategies for diagnosing deep vein thrombosis: a cost-effectiveness analysis. American Journal of Medicine, 2001, 110, 33-40.	1.5	71
41	Validation of a risk score identifying patients with acute pulmonary embolism, who are at low risk of clinical adverse outcome. Thrombosis and Haemostasis, 2004, 91, 1232-1236.	3.4	71
42	Risk of recurrent venous thromboembolism according to baseline risk factor profiles. Blood Advances, 2018, 2, 788-796.	5.2	71
43	Diagnosis of venous thromboembolism: an update. Vascular Medicine, 2010, 15, 399-406.	1.5	65
44	The Swiss cohort of elderly patients with venous thromboembolism (SWITCO65+): rationale and methodology. Journal of Thrombosis and Thrombolysis, 2013, 36, 475-483.	2.1	63
45	Accuracy or Outcome in Suspected Pulmonary Embolism. New England Journal of Medicine, 2006, 354, 2383-2385.	27.0	61
46	Seasonal variation in deep vein thrombosis. BMJ: British Medical Journal, 1996, 312, 284-285.	2.3	61
47	D-dimer plasma measurement in patients undergoing major hip surgery: Use in the prediction and diagnosis of postoperative proximal vein thrombosis. Thrombosis Research, 1994, 74, 487-493.	1.7	59
48	Treatment of venous thromboembolism with rivaroxaban in relation to body weight. Thrombosis and Haemostasis, $2016, 116, 739-746$.	3.4	58
49	Limited usefulness of D-dimer in suspected deep vein thrombosis of the upper extremities. Blood Coagulation and Fibrinolysis, 2006, 17, 225-226.	1.0	55
50	Single-Blind, Randomized Study Comparing Chromated Glycerin, Polidocanol Solution, and Polidocanol Foam for Treatment of Telangiectatic Leg Veins. Dermatologic Surgery, 2004, 30, 367-372.	0.8	54
51	Challenges in the Diagnosis Acute Pulmonary Embolism. American Journal of Medicine, 2008, 121, 565-571.	1.5	54
52	Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE. Journal of Thrombosis and Thrombolysis, 2020, 50, 267-277.	2.1	54
53	Fondaparinux: a new synthetic pentasaccharide for thrombosis prevention. Lancet, The, 2002, 359, 1710-1711.	13.7	52
54	Development of a Risk Prediction Score for Occult Cancer in Patients With VTE. Chest, 2017, 151, 564-571.	0.8	51

#	Article	IF	Citations
55	Thrombolytic Treatment with Recombinant Tissue-Type Plasminogen Activator in a Patient with Massive Pulmonary Embolism. Annals of Internal Medicine, 1985, 103, 64.	3.9	49
56	Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Thrombosis and Haemostasis, 2015, 114, 645-650.	3.4	48
57	Global Anticoagulant Registry in the Field – Venous Thromboembolism (GARFIELD-VTE). Thrombosis and Haemostasis, 2016, 116, 1172-1179.	3.4	46
58	Treatment of Right Heart Thrombi Associated with Acute Pulmonary Embolism. American Journal of Medicine, 2017, 130, 588-595.	1.5	45
59	Clinical relevance of distal deep vein thrombosis. Review of literature data. Thrombosis and Haemostasis, 2006, 95, 56-64.	3.4	42
60	Screening Tests for Thrombophilic Patients: Which Tests, for Which Patient, by Whom, When, and Why?. Seminars in Thrombosis and Hemostasis, 1998, 24, 321-327.	2.7	41
61	Fondaparinux for Isolated Superficial Vein Thrombosis of the Legs. Chest, 2012, 141, 321-329.	0.8	41
62	Association of anticardiolipin antibodies and abnormal nailfold capillaroscopy in patients with systemic lupus erythematosus. Lupus, 1995, 4, 142-144.	1.6	40
63	Correlation between cardiac biomarkers and right ventricular enlargement on chest CT in non massive pulmonary embolism. Thrombosis Research, 2008, 121, 617-624.	1.7	39
64	Monitoring of Heparin Treatment. Comparison between Thrombin Time, Activated Partial Thromboplastin Time, and Plasma Heparin Concentration, and Analysis of the Behavior of Antithrombin III. American Journal of Clinical Pathology, 1980, 74, 68-73.	0.7	38
65	Contribution of D-dimer plasma measurement and lower-limb venous ultrasound to the diagnosis of pulmonary embolism: A decision analysis model. American Heart Journal, 1994, 127, 624-635.	2.7	37
66	Isolated Distal Deep Vein Thrombosis: Perspectives from the GARFIELD-VTE Registry. Thrombosis and Haemostasis, 2019, 119, 1675-1685.	3.4	34
67	Hemodynamic effects of intermittent pneumatic compression of the lower limbs during laparoscopic cholecystectomy. American Journal of Surgery, 1995, 170, 395-398.	1.8	31
68	D-dimer for the diagnosis of pulmonary embolism: a call for sticking to evidence. Intensive Care Medicine, 2005, 31, 1-2.	8.2	31
69	Early Use of Echocardiography in Patients With Acute Pulmonary Embolism: Findings From the RIETE Registry. Journal of the American Heart Association, 2018, 7, e009042.	3.7	31
70	Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELDâ€VTE patients. Journal of Thrombosis and Haemostasis, 2019, 17, 1694-1706.	3.8	30
71	Influence of Variability of Interpretation of Contrast Venography for Screening of Postoperative Deep Venous Thrombosis on the Results of a Thromboprophylactic Study. Thrombosis and Haemostasis, 1993, 70, 573-575.	3.4	29
72	Venous thromboembolism diagnosis: unresolved issues. Thrombosis and Haemostasis, 2015, 113, 1184-1192.	3.4	28

#	Article	IF	Citations
73	Upper Extremity DVT versus Lower Extremity DVT: Perspectives from the GARFIELD-VTE Registry. Thrombosis and Haemostasis, 2019, 119, 1365-1372.	3.4	28
74	Assessment of Outcomes Among Patients With Venous Thromboembolism With and Without Chronic Kidney Disease. JAMA Network Open, 2020, 3, e2022886.	5.9	28
75	Duration of Anticoagulation Therapy for Venous Thromboembolism. Hematology American Society of Hematology Education Program, 2008, 2008, 252-258.	2.5	25
76	Effect of pharmaceutical interventions targeting thromboxane receptors and thromboxane synthase in cardiovascular and renal diseases. Future Cardiology, 2009, 5, 479-493.	1.2	24
77	Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE. Chest, 2016, 150, 1059-1068.	0.8	24
78	AngioJet rheolytic thrombectomy in patients presenting with high-risk pulmonary embolism and cardiogenic shock: a feasibility pilot study. EuroIntervention, 2013, 8, 1419-1427.	3.2	24
79	Clinical usefulness of D-dimer testing in cancer patients with suspected pulmonary embolism. Thrombosis and Haemostasis, 2006, 95, 715-9.	3.4	24
80	Effects of Low-Dose Nifedipine on a Cold Provocation Test in Patients with Raynaud $\hat{E}\frac{1}{4}$ s Disease. Journal of Cardiovascular Pharmacology, 1990, 15, 853-855.	1.9	23
81	Promoter Dependence of Transgene Expression by Lentivirus-Transduced Human Blood-Derived Endothelial Progenitor Cells. Stem Cells, 2006, 24, 199-208.	3.2	23
82	Effects of impaired renal function on levels and performance of D-dimer in patients with suspected pulmonary embolism. Thrombosis and Haemostasis, 2014, 112, 614-620.	3.4	23
83	DVT Management andÂOutcome Trends, 2001 to 2014. Chest, 2016, 150, 374-383.	0.8	23
84	Provoked versus unprovoked venous thromboembolism: Findings from GARFIELDâ€ V TE. Research and Practice in Thrombosis and Haemostasis, 2021, 5, 326-341.	2.3	23
85	Acute venous thromboembolism after non-major orthopaedic surgery or post-traumatic limb immobilisation. Thrombosis and Haemostasis, 2011, 105, 739-741.	3.4	22
86	Comparison of Cardiac and Non-Cardiac Biomarkers for Risk Stratification in Elderly Patients with Non-Massive Pulmonary Embolism. PLoS ONE, 2016, 11, e0155973.	2.5	22
87	Comparative effectiveness of oral anticoagulants in venous thromboembolism: GARFIELD-VTE. Thrombosis Research, 2020, 191, 103-112.	1.7	22
88	Human tibia Bone Marrow: Defining a Model for the Study of Haemodynamics as a Function of Age by Near Infrared Spectroscopy. Journal of Physiological Anthropology and Applied Human Science, 2003, 22, 211-218.	0.4	22
89	Venous Thromboembolism. Circulation, 2011, 123, 2189-2191.	1.6	21
90	Clinical Prognosis of Nonmassive Central and Noncentral Pulmonary Embolism. Chest, 2017, 151, 829-837.	0.8	21

#	Article	IF	Citations
91	Effects of exercise test on plasma markers of an activation of coagulation and/or fibrinolysis in patients with symptomatic or silent myocardial ischemia. Thrombosis Research, 1992, 65, 27-32.	1.7	19
92	Thrombolytic Therapy in Pulmonary Embolism. Seminars in Vascular Medicine, 2001, 01, 213-220.	2.1	19
93	External validation and comparison of recently described prediction rules for suspected pulmonary embolism. Current Opinion in Pulmonary Medicine, 2004, 10, 345-349.	2.6	19
94	Thrombolytic Therapy Compared with Mechanical Recanalization in Non-acute Peripheral Arterial Occlusions: A Randomized Trial. Journal of Vascular and Interventional Radiology, 1995, 6, 775-781.	0.5	17
95	Effect of age on the performance of single detector helical computed tomography in suspected pulmonary embolism. Thrombosis and Haemostasis, 2004, 91, 296-299.	3.4	17
96	A new rapid point-of-care D-dimer enzyme-linked immunosorbent assay (Stratus CS D-dimer) for the exclusion of venous thromboembolism. Blood Coagulation and Fibrinolysis, 2004, 15, 435-438.	1.0	17
97	Association Between Newborn Birth Weight and the Risk of Postpartum Maternal Venous Thromboembolism. Circulation, 2015, 131, 1471-1476.	1.6	17
98	Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism. European Heart Journal, 2014, 35, 1836-1843.	2.2	16
99	Pregnancy-Associated Venous Thromboembolism: Insights from GARFIELD-VTE. TH Open, 2021, 05, e24-e34.	1.4	16
100	The Place of D-Dimer Testing in an Integrated Approach of Patients Suspected of Pulmonary Embolism. Seminars in Thrombosis and Hemostasis, 1998, 24, 409-412.	2.7	15
101	Treating Patients with Venous Thromboembolism: Initial Strategies and Long-Term Secondary Prevention. Seminars in Vascular Medicine, 2005, 5, 276-284.	2.1	15
102	Characterization of Human Late Outgrowth Endothelial Progenitor-Derived Cells under Various Flow Conditions. Journal of Vascular Research, 2011, 48, 443-451.	1.4	15
103	Prognostic value of the Geneva prediction rule in patients with pulmonary embolism. Thrombosis Research, 2013, 132, 32-36.	1.7	15
104	Predictors of thromboprophylaxis in hospitalised medical patients. Thrombosis and Haemostasis, 2015, 113, 1127-1134.	3.4	15
105	Understanding haemorrhagic risk following thrombolytic therapy in patients with intermediate-risk and high-risk pulmonary embolism: a hypothesis paper. Open Heart, 2018, 5, e000735.	2.3	15
106	Evaluation of Advanced D-dimer assay for the exclusion of venous thromboembolism. Thrombosis Research, 2002, 107, 197-200.	1.7	14
107	Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials. Thrombosis Research, 2017, 149, 29-37.	1.7	14
108	Influence of body mass index on clinical outcomes in venous thromboembolism: Insights from GARFIELDâ€VTE. Journal of Thrombosis and Haemostasis, 2021, 19, 3031-3043.	3.8	14

#	Article	IF	CITATIONS
109	Life-Threatening Pulmonary Embolism Associated with a Thrombus Straddling a Patent Foramen Ovale: Report of a Case. Journal of Cardiac Surgery, 2008, 23, 376-378.	0.7	13
110	Pulmonary cement embolism after vertebroplasty. Thrombosis and Haemostasis, 2006, 95, 388-9.	3.4	13
111	Symptoms and clinical relevance: A dilemma for clinical trials on prevention of venous thromboembolism. Thrombosis and Haemostasis, 2013, 109, 585-588.	3.4	12
112	Direct Oral Anticoagulants for Acute Venous Thromboembolism. Circulation, 2014, 129, 725-727.	1.6	12
113	Recurrence of venous thromboembolism in patients with recent gestational deep vein thrombosis or pulmonary embolism: Findings from the RIETE Registry. European Journal of Internal Medicine, 2016, 32, 53-59.	2,2	12
114	Comparative clinical prognosis of massive and nonâ€massive pulmonary embolism: A registryâ€based cohort study. Journal of Thrombosis and Haemostasis, 2021, 19, 408-416.	3.8	12
115	On the Association of Elevated tPA/PAI-1 Complex and von Willebrand Factor With Recurrent Myocardial Infarction. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 1857-1859.	2.4	11
116	Uptake of new treatment strategies for deep vein thrombosis: an international audit. International Journal for Quality in Health Care, 2004, 16, 193-200.	1.8	11
117	Generation of Human Inflammation-Resistant Endothelial Progenitor Cells by A20 Gene Transfer. Journal of Vascular Research, 2010, 47, 157-167.	1.4	11
118	Echocardiography does not predict mortality in hemodynamically stable elderly patients with acute pulmonary embolism. Thrombosis Research, 2016, 145, 67-71.	1.7	11
119	Women, thrombosis, and cancer: A gender-specific analysis. Thrombosis Research, 2017, 151, S21-S29.	1.7	11
120	Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin. Thrombosis Research, 2018, 168, 121-129.	1.7	11
121	Direct oral anticoagulants: a guide for daily practice. Swiss Medical Weekly, 2016, 146, w14286.	1.6	11
122	Thromboembolism and antithrombotic therapy in peripheral arterial disease. Journal of the American College of Cardiology, 1986, 8, 98B-103B.	2.8	10
123	Integrierte Diagnostik bei Verdacht auf tiefe Venenthromben und Lungenembolie. Vasa - European Journal of Vascular Medicine, 2002, 31, 15-21.	1.4	10
124	Inferior vena cava agenesis: Association with bilateral lower-limb deep vein thrombosis in young males. Thrombosis and Haemostasis, 2009, 102, 795-798.	3.4	10
125	Anticoagulation Management Practices and Outcomes in Elderly Patients with Acute Venous Thromboembolism: A Clinical Research Study. PLoS ONE, 2016, 11, e0148348.	2.5	10
126	Follow-up after partial interruption of the vena cava with the $G\tilde{A}^{1}/4$ nther filter. CardioVascular and Interventional Radiology, 1990, 13, 378-380.	2.0	9

#	Article	IF	CITATIONS
127	The influence of anemia on clinical outcomes in venous thromboembolism: Results from GARFIELD-VTE. Thrombosis Research, 2021, 203, 155-162.	1.7	9
128	Management strategies and clinical outcomes in patients with inferior vena cava thrombosis: Data from GARFIELDâ€VTE. Journal of Thrombosis and Haemostasis, 2021, , .	3.8	8
129	Postoperative Deep Venous Thrombosis (DVT) and Low-Molecular Weight Heparin (LMWH) Type and Dosage. Thrombosis and Haemostasis, 1993, 69, 402-403.	3.4	7
130	Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis. Thrombosis and Haemostasis, 2002, 87, 586-92.	3.4	7
131	Venous Thrombosis: Risk Factors and Management. Herz, 2007, 32, 27-34.	1.1	6
132	Multiple arteriovenous malformations caused by RASA1 gene mutation presenting during pregnancy – a case report and review of the literature. Vasa - European Journal of Vascular Medicine, 2019, 48, 276-280.	1.4	6
133	Management of severe ischemia of the hand following intra-arterial injection. Thrombosis and Haemostasis, 2005, 94, 219-21.	3.4	6
134	Portal vein thrombosis following a primary cytomegalovirus infection in an immunocompetent adult. Thrombosis and Haemostasis, 2006, 95, 199-201.	3.4	6
135	VENOGRAPHY OF THE LOWER LIMBS. Investigative Radiology, 1992, 27, 1009-1011.	6.2	5
136	Cyclosporine toxicity in renal transplant recipients detected by nailfold capillaroscopy with Na-fluorescein. Kidney International, 2000, 58, 2559-2563.	5.2	5
137	Influence of specific alternative diagnoses on the probability of pulmonary embolism. Thrombosis and Haemostasis, 2006, 95, 958-962.	3.4	5
138	Diagnosis of pulmonary embolism: in transition. Current Opinion in Internal Medicine, 2006, 5, 577-583.	1.5	5
139	Secondary Prevention of Venous Thromboembolism. Circulation, 2015, 132, 1856-1859.	1.6	5
140	Diagnostic approaches to suspected deep vein thrombosis and pulmonary embolism. The Hematology Journal, 2003, 4, 97-103.	1.4	5
141	Transluminal angioplasty of the aorta, renal and mesenteric arteries in Takayasu arteritis: Report of two cases. European Journal of Vascular Surgery, 1992, 6, 567-571.	0.9	4
142	Role of D-Dimers in the Exclusion of Pulmonary Embolism. Seminars in Respiratory and Critical Care Medicine, 1996, 17, 31-37.	2.1	4
143	Diagnostic Strategies for Suspected Pulmonary Embolism Among Outpatients. Seminars in Vascular Medicine, 2001, 01, 189-194.	2.1	4
144	Duration of anticoagulation after VTE: guided by ultrasound?. Nature Reviews Cardiology, 2009, 6, 499-500.	13.7	2

#	Article	IF	Citations
145	Treatment strategies for acute pulmonary embolism. Expert Opinion on Pharmacotherapy, 2009, 10, 1159-1171.	1.8	2
146	Contrastâ€enhanced sonographic diagnosis of unsuspected internal iliac vein thrombosis. Journal of Clinical Ultrasound, 2011, 39, 553-555.	0.8	2
147	A half-century of developments in the field of antithrombotics–A tribute to Jack Hirsh. European Journal of Internal Medicine, 2020, 75, 23-24.	2.2	2
148	<scp>d</scp> -Dimer and Venous Thromboembolism. Annals of Internal Medicine, 2004, 141, 481.	3.9	2
149	Single Complete Compression Ultrasonography for Suspected Deep Venous Thrombosis: Ideal in Routine Clinical Practice?. Annals of Internal Medicine, 2004, 141, 888.	3.9	2
150	Aspirin for venous thromboembolism prevention and treatment: a renewal?. Polish Archives of Internal Medicine, 2012, 122, 461-463.	0.4	1
151	Review: ELISA <scp>D</scp> -dimer is sensitive but not specific in diagnosing pulmonary embolism in an ambulatory clinical setting. ACP Journal Club, 2003, 138, 24.	0.1	1
152	An Unusual Cause of Hand Cellulitis. Circulation, 2007, 115, e65-6.	1.6	0
153	Faut-il traiter toutes les thromboses post-op \tilde{A} ©ratoires ?. Praticien En Anesthesie Reanimation, 2011, 15, H5-H9.	0.0	0
154	High-sensitive cardiac troponin T as a marker of hemorrhagic complications in elderly patients anticoagulated for non-massive pulmonary embolism. Thrombosis Research, 2020, 185, 5-12.	1.7	0
155	Clinical Predictors of Prophylaxis Use Prior to the Onset of Acute Venous Thromboembolism in Hospitalized Patients: Swiss Venous ThromboEmbolism Registry (SWIVTER). Blood, 2008, 112, 3019-3019.	1.4	0
156	International Clinical Practice Guidelines for the Treatment and Prophylaxis of Thrombosis Associated with Central Venous Catheters in Patients with Cancer. Blood, 2012, 120, 4357-4357.	1.4	0
157	International Good Clinical Practices Guidelines (GCPG) for Antithrombotics in CANCER Patients. Blood, 2012, 120, 1161-1161.	1.4	0
158	Age-Adjusted D-Dimer Cut-off Levels to Rule out Pulmonary Embolism: A Prospective Outcome Study. Blood, 2013, 122, LBA-4-LBA-4.	1.4	0
159	A rebuttal: withholding anticoagulation in patients with suspected pulmonary embolism and a low probability ventilation perfusion scan: an unacceptable risk. Thrombosis and Haemostasis, 2002, 88, 702.	3.4	0
160	Review: ELISA D-dimer is sensitive but not specific in diagnosing pulmonary embolism in an ambulatory clinical setting. ACP Journal Club, 2003, 138, 24.	0.1	0